HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

SHISEIDO COSMETICS SALES UP 1.5% IN FISCAL 1995 FIRST HALF

This article was originally published in The Rose Sheet

Executive Summary

SHISEIDO COSMETICS SALES UP 1.5% IN FISCAL 1995 FIRST HALF (April 1 to Sept. 30) the company reported in an Oct. 28 release. Cosmetic sales, which account for 71.5% of total sales, were Y140.67 bil. or $1.42 bil. for the six months, based on a Sept. 30 exchange rate of $1 = Y99.05. Sales for the cosmetic segment were boosted in part by the recently introduced Receinte Perfect Rouge N lipstick and by Vivace Hair Fresh hair deodorant, which "contributed significantly to the increase" in cosmetics sales, the company said. Shiseido also highlighted contributions from its main brand in the self-selection market, Whitia, and Pureness, a new skin care line that was launched in August and September in the U.S. and Europe, respectively ("The Rose Sheet" June 13, p. 7).

Latest Headlines
See All
UsernamePublicRestriction

Register

RS001022

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel